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Abstract: INTRODUCTION Marfan syndrome (MFS) and related connective tissue disorders (CTDs) are
increasingly recognised. Genetic testing has greatly improved the diagnostic outcome/power over the last
two decades. In this study we describe a multicentre cohort of adults with MFS and related CTDs, with
a particular focus on results from genetic testing. METHODS All patients with MFS and related CTDs
were identified from the databases of five centres in the canton of Zurich. Echocardiographic and clinical
findings including systemic Marfan score, use of medication and genetic results were retrospectively anal-
ysed. MFS was diagnosed using the revised Ghent criteria (including FBN1 genetic testing if available);
other CTDs (Loeys-Dietz syndrome) were diagnosed by genetic testing only. RESULTS A cohort of 103
patients were identified (62 index patients, 41 relatives of family members): 96 patients with MFS and 7
patients with other CTD, 54 males (52%), median age 23 years (range 1ndash;75). The median systemic
Marfan score was 5 (range 0ndash;18). Only 40 patients (40/103, 39%) fulfilled criteria for systemic
involvement (ge;7 points). A history of aortic dissection was present in 14 out of 103 patients (14%).
Echocardiographic data were available for all: aortic root enlargement (Z-score ge;2 in adults, Z-score
ge;3 in children) was found in 49 patients (48%) and mitral valve prolapse in 64 (62%). Genetic testing
had been performed in 80 patients (78%); FBN1 mutations were present in 69 patients (86%); other
pathogenic mutations could be identified in seven patients (9%); no disease-causing mutation was found
in four patients, three of them fulfilling the Ghent criteria of MFS. Of the mutation-positive patients, 33
had a systemic score of ge;7 and 43 had a systemic score of ge;5. Revised Ghent criteria were fulfilled
in 70 patients: in 69 patients with FBN1 mutations and 1 patient with another CTD. Recommended
treatment (beta-blocker, angiotensin receptor blocker) was taken by 63% of patients. CONCLUSIONS In
this cohort a high percentage of patients fulfilling the revised Ghent criteria for MFS underwent genetic
testing, often leading to or confirming the diagnosis of MFS. Other CTDs could be discriminated best by
genetic testing. With respect to the diagnosis of MFS and related CTDs, the usefulness of the systemic
score is limited, showing the importance of genetic testing, which enabled definitive diagnosis in 95% of
tested patients. Patient education on medical treatment still has to be improved. (Trial registration no:
KEK-ZH-Nr. 2013-0241).
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Summary
INTRODUCTION: Marfan syndrome (MFS) and related
connective tissue disorders (CTDs) are increasingly
recognised. Genetic testing has greatly improved the di-
agnostic outcome/power over the last two decades. In this
study we describe a multicentre cohort of adults with MFS
and related CTDs, with a particular focus on results from
genetic testing.
METHODS: All patients with MFS and related CTDs were
identified from the databases of five centres in the canton
of Zurich. Echocardiographic and clinical findings includ-
ing systemic Marfan score, use of medication and genetic
results were retrospectively analysed. MFS was diag-
nosed using the revised Ghent criteria (including FBN1 ge-
netic testing if available); other CTDs (Loeys-Dietz syn-
drome) were diagnosed by genetic testing only.
RESULTS: A cohort of 103 patients were identified (62
index patients, 41 relatives of family members): 96 pa-
tients with MFS and 7 patients with other CTD, 54 males
(52%), median age 23 years (range 1–75). The median
systemic Marfan score was 5 (range 0–18). Only 40 pa-
tients (40/103, 39%) fulfilled criteria for systemic involve-
ment (≥7 points). A history of aortic dissection was present
in 14 out of 103 patients (14%). Echocardiographic data
were available for all: aortic root enlargement (Z-score ≥2
in adults, Z-score ≥3 in children) was found in 49 patients
(48%) and mitral valve prolapse in 64 (62%). Genetic test-
ing had been performed in 80 patients (78%); FBN1 muta-
tions were present in 69 patients (86%); other pathogen-
ic mutations could be identified in seven patients (9%);
no disease-causing mutation was found in four patients,
three of them fulfilling the Ghent criteria of MFS. Of the
mutation-positive patients, 33 had a systemic score of ≥7
and 43 had a systemic score of ≥5. Revised Ghent crite-
ria were fulfilled in 70 patients: in 69 patients with FBN1
mutations and 1 patient with another CTD. Recommend-
ed treatment (beta-blocker, angiotensin receptor blocker)
was taken by 63% of patients.
CONCLUSIONS: In this cohort a high percentage of pa-
tients fulfilling the revised Ghent criteria for MFS under-
went genetic testing, often leading to or confirming the di-
agnosis of MFS. Other CTDs could be discriminated best
by genetic testing. With respect to the diagnosis of MFS
and related CTDs, the usefulness of the systemic score is
limited, showing the importance of genetic testing, which
enabled definitive diagnosis in 95% of tested patients. Pa-
tient education on medical treatment still has to be im-
proved. (Trial registration no: KEK-ZH-Nr. 2013-0241)
Keywords: Marfan syndrome, connective tissue disor-
ders, Loeys-Dietz syndrome, genetic testing in Marfan
syndrome and related conditions
Introduction
Marfan syndrome (MFS) is an autosomal-dominant con-
nective tissue disorder caused by mutations in the fib-
rillin-1 (FBN1) gene [1]. Over 1000 different mutations
causing MFS and related disorders have been described so
far [2, 3]. About 25% of the mutations are de-novo.
The mutations lead to a qualitative or quantitative lack
of FBN1 protein, a 350 kDa glycoprotein that is a major
component of elastin associated microfibrils in the extra-
cellular matrix [4]. The structural change of FBN1 pro-
tein in MFS explains the resulting changes in elastin-con-
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taining tissue such as abnormalities of the eye (ectopia
lentis), aorta, heart valves and, although partially, skeleton
(dolichostenomelia, arachnodactyly, pectus deformity and
joint laxity) [5].
There is a wide spectrum of clinical expression, ranging
from severe neonatal MFS or fatal aortic dissection to
milder forms without cardiovascular involvement. Cardiac
problems include aortic dilatation, aortic dissection, aortic
regurgitation, mitral valve prolapse and sudden cardiac
death. Nowadays, MFS is diagnosed using the revised
Ghent criteria of 2010 [6]. The most important differential
diagnoses of MFS are shown in table 1. Frequently, other
CTDs, including more aggressive Loeys-Dietz syndrome
(LDS) and ACTA2 mutations can be identified by genetic
testing only.
Before genetic testing became widely available, MFS was
diagnosed solely on the basis of clinical findings (Ghent
criteria). However, these clinical diagnostic criteria are im-
perfect. Genetic testing has much improved the diagnostic
process over the last two decades. In this retrospective co-
hort study, we summarise clinical characteristics and find-
ings from genetic testing in a multicentre cohort.
Materials and methods
Setting
The study was based on a retrospective chart review and
data analysis between 2001 and 2013 at five large hospitals
in the Canton of Zurich: University Hospital of Zurich
(Department of Cardiology), University Children Hospital
of Zurich (Divisions of Metabolism and Cardiology),
Stadtspital Triemli (Department of Cardiology), Klinik Im
Park (Cardiovascular Centre) and Kantonsspital Win-
terthur (Department of Cardiology).
The study was approved by the ethics review committee of
the Canton of Zurich (KEK-ZH-Nr. 2013-0241).
Patients
Within the participating institutions all patients followed
up in their dedicated programmes for Marfan syndrome,
suspected Marfan syndrome or Marfan-like conditions
were identified from their clinical databases. For the pur-
pose of this study, the charts of all patients with a diagnosis
of MFS were carefully reviewed. All patients had at least
one echocardiographic examination or other imaging of the
aorta, and at least one consultation at one of the study cen-
tres between 2001 and 2013.
Definitions
The aortic root was measured at the sinuses of Valsalva.
In children and adolescents (2–18 years old), the root was
measured in mm from inner edge to inner edge during dias-
tole, thus excluding the thickness of aortic wall. In adults,
the aortic root was measured in mm from leading edge to
leading edge at end-diastole.
Aortic root ectasia is defined as a Z-score ≥2 in adults
or ≥3 in children. The Z-scores were calculated using the
nomograms for aortic root diameters by Gautier for the
group aged <15 years and by Devereux for adults (age >15
years) [8, 9]. For the calculation of the Z-scores for the as-
cending aorta the formula according to Campens was used
[8, 9].
In patients who underwent aortic root surgery, the preoper-
ative diameters of the aorta were used as baseline, if avail-
able.
Diagnosis of Marfan syndrome
The diagnosis of MFS was defined as fulfilment the 2010
Ghent criteria [6]. These criteria include aortic dilatation,
ocular involvement, systemic findings and results from ge-
netic testing. Molecular genetic testing included analysis
of FBN1 and MFS-related genes (see table 1) [6]. In the
absence of a positive family history of MFS, a diagnosis
of MFS can be confirmed in the following situations: (a)
presence of aortic root aneurysm (aortic Z-score ≥2 above
Table 1: Differential diagnosis of Marfan syndrome.





MFS AD 1:5000 ++ + IA, MVP FBN1
LDS1, LDS2 AD Unknown ++ +++ BAV, IA, MVP TGFBR1, TGFBR2
LDS3 AD Unknown ++ ++/+++ BAV, IA, MVP SMAD3
LDS4, LDS5 AD Unknown ++/+++ + BAV, MVP TGFB2, TGFB3
LDS6 AD Unknown ++ + MVP SMAD2












AD 1:50 000 + ++ IA, MVP COL3A1
Aortic valve disease AD >1:100 + + BAV NOTCH1
ELN-related cutis laxa AD <1:4 Mio. + + - ELN
ACTA2 = actin-alpha; AD = autosomal dominant; BAV = bicuspid aortic valve; BGN = biglycan gene; COL3A1 = type 3 collagen pro-α1; ELN = elastin; FBN1 = fibrillin 1; FOXE3 =
forkhead transcription factor 3; HCN4 = hyperpolarisation-activated cyclic nucleotide-gated channels gene 4; IA = interatrial septum aneurysm; LDS = Loeys-Dietz syndrome; LOX
= lysyl oxidase; MAT2A = methionine adenosyltransferase 2A; MFAP = microfibrillar-associated protein; MFS = Marfan syndrome; MVP = mitral valve prolapse; MYH11 = myosin
heavy chain 11; MYLK = myosin light-chain kinase; NOTCH1= neurogenic locus notch homologue protein 1; PRKG1 = cGMP-dependent protein kinase 1; SKI = Sloan Kettering
Institute proto-oncoprotein; SMAD = SMAD proteins homologues of both the drosophila protein, mothers against decapentaplegic (MAD) and the Caenorhabditis elegans protein
SMA; TAAD = thoracic aortic aneurysm and dissection; TGFBR1 and 2 = transforming growth factor β 1 and 2 Table modified from Attenhofer Jost CH, Greutmann M, et al. [7]
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20 years old or a Z-score ≥3 below 20 years) and ectopia
lentis; (b) aortic root Z-score ≥2 above 20 years old or a
Z-score ≥3 below 20 years and FBN1 mutation; (c) aortic
root Z-score ≥2 above 20 years old or a Z-score ≥3 below
20 years and systemic involvement (systemic score ≥7); or
(d) ectopia lentis and the presence of an FBN1 mutation
known to cause an aortic phenotype [6].
In the presence of a positive family history for MFS (di-
agnosed in the index patients with the criteria mentioned
above), the presence of only one of the following features
confirms MFS: ectopia lentis OR aortic root aneurysm
(aortic Z-score ≥2 above 20 years old or a Z-score ≥3 be-
low 20 years) or aortic dissection OR a systemic involve-
ment (systemic score ≥7) [6].
Genetic testing
DNA extraction from fibroblasts or ethylenediamine
tetraacetic acid (EDTA)-anticoagulated whole blood sam-
ples, as well as exon-by-exon polymerase chain-reaction
testing, denaturing high performance liquid chromatogra-
phy (DHPLC) screening, and/or direct Sanger sequenc-
ing and multiplex ligation-dependent probe amplification
(MLPA) analysis were performed as previously described
[10–12].
Statistical analysis
Continuous variables are presented as mean and standard
deviation or median with interquartilce range (IQR) as ap-
propriate. Categorical variables are presented as percent-
ages. For the analysis of Z-scores, average absolute de-
viation was used. Statistical comparisons of distribution
between groups were made using the student t-tests. The




We identified a total of 103 patients from 62 distinct fami-
lies. Of these, 96 (93%) had MFS, 7 (7%) LDS or another
MFS-related CTD. Sixty-two patients (60%) of the cohort
were newly diagnosed index patients, whereas 41 (40%)
had a family member with an established diagnosis. Base-
line patient characteristics are summarised in table 2.
Results of genetic testing
Genetic testing was performed in a total of 80/103 (78%)
patients. In most of these patients, disease causing muta-
tions in the FBN1 gene were found (69/80, 86%). One pa-
tient had a TGFBR1 (LDS1), three a TGFBR2 (LDS2), two
a SMAD3 (LDS3) and one a TGFB2 mutation (LDS4) mu-
tation. In four patients, three of whom fulfilled the Ghent
criteria for MFS, no disease-causing mutations could be
identified.
Clinical findings
The clinical findings are shown in tables 2 and 3. Median
age was 23 years (range 1–75) and 43/103 patients (42%)
were under the age of 18 years.
In 40 patients (40/103, 39%) a systemic score of ≥7 was
documented. Of the 96 patients with a definitive diagnosis
of MFS, 38 (40%) had a systemic score of ≥7, 44 (46%) a
systemic score of ≥6, 50 (52%) a systemic score of ≥5 and
59 (61%) a systemic score of ≥4.
Other features commonly seen included hypermobility of
the joints in 28 (27%), leg length discrepancy in 10 (10%),
arthralgia in 12 (12%) and varicose veins in 8 (8%) pa-
tients. Hypertelorism and a cleft palate were present in on-
ly one patient with LDS; a bifid uvula was present in four
(4%) patients, three of them with LDS (LDS1 and LDS3)
and one with MFS and a disease-causing mutation in the
FBN1 gene. Twelve (12%) patients had a history of scolio-
sis surgery and prior foot surgery was reported by 7 (7%)
patient; 12 (12%) patients had previous lensectomy.
Cardiovascular findings
The echocardiographic findings are summarised in table 4.
Aortic root enlargement was found in 49 patients (49/103,
48%). Mitral valve prolapse was common (64/103 patients,
62%); however, severe mitral regurgitation was rare. Left
ventricular ejection fraction was <50% in nine patients (9/
103, 9%). There was no difference in echocardiographic
findings between FBN1-positive patients and those with
other CTDs (for each p-value see table 4).
Cardiac surgery
Cardiac surgery was performed in 34 patients (33%): 28
patients (27%) underwent aortic root surgery, 2 (2%) mitral
valve surgery, (3%) combined aortic root and mitral valve
surgery, and 1 (1%) combined aortic root and tricuspid
valve surgery. Among patients undergoing aortic root







Mean age (years), range 1–75 years 23 17 15
Men 54 (52%) 31 (45%) 3 (43%)
Ghent positive 95 (92%) 64 (93%) 7 (100%)
Ectopia lentis 29 (28%) 20 (29%) 0
Aortic dissection type A 10 (10%) 4 (6%) 0
Aortic dissection type B 4 (4%) 0 1 (14%)
Spontaneous pneumothorax 3 (3%) 3 (4%) 0
Stretch marks 22 (21%) 20 (29%) 1 (14%)
Dural ectasia 13 (13%) 5 (7%) 0
Family history of Marfan syndrome 41 (40%) 30 (43%) 1 (14%)
CTD = connective tissue disorder; FBN1 = fibrillin 1
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surgery, 30 (30/31, 97%) had MFS and only 1 patient LDS.
Fifty-eight percent (18/31) of the aortic root aneurysms
were repaired using the valve-sparing Tirone David tech-
nique (in one patient combined with tricuspid valve re-
pair), whereas 35% (11/31) received a composite graft (in
two patients combined with mitral valve replacement and
one another patient combined with mitral valve repair).
One patient received an isolated replacement of the as-
cending aorta, one patient underwent isolated mitral valve
replacement and another one mitral valve repair. In two pa-
tients, details about the exact surgical technique for aortic
root treatment were not available.
Four out of five patients (80%) who underwent mitral
valve surgery had genetically proven MFS. In 60% (3/5) of
these patients, replacement of the valve was needed; 40%
(2/5) were repaired.
One patient of the cohort needed an implantable car-
dioverter defibrillator (ICD) because of ventricular tachy-
cardia and a positive family history for sudden cardiac
death. Two more patients needed implantation of pacemak-
er owing to postoperative complete atrioventricular block.
All cardiac interventions are summarised in table 5.
Cardiovascular complications and death
Fourteen percent (14/103) of the cohort experienced an
aortic dissection; in 10/14 (71%) patients it was a type A
dissection, the others had type B aortic dissection. Overall,
93% of these patients (13/14) had MFS, only one patient
had LDS.
Three patients died, all of whom had MFS. A 15-year-
old girl died from a hypoxic brain injury after out-of-hos-
pital resuscitation because of ventricular fibrillation and
an epileptic storm. A 16-year-old boy died from high-
grade osteosarcoma in the lateral left femoral condyle.
A 45-year-old woman died from infectious complications
(mediastinitis) after repeated complex surgeries for type A
aortic dissection.







Ectopia lentis 29 (28%) 20 (29%) 0
Family history of Marfan syndrome 41 (40%) 30 (43%) 1 (14%)
Pectus carinatum 20 (19%) 16 (23%) 3 (43%)
Pectus excavatum 33 (32%) 22 (32%) 3 (43%)
Arm span/height ratio >1.05 2 (2%) 2 (3%) 0
Wrist or thumb sign 17 (17%) 13 (19%) 2 (29%)
Wrist and thumb sign 26 (25%) 21 (30%) 2 (29%)
Scoliosis 53 (51%) 37 (54%) 4 (57%)
Back surgery 12 (12%) 8 (12%) 1 (14%)
Reduced extension of the elbows (<170°) 8 (8%) 7 (10%) 0
Pes planus or valgus 54 (52%) 43 (62%) 5 (71%)
Protrusio acetabuli 6 (6%) 4 (6%) 0
Joint hypermobility 28 (27%) 21 (30%) 5 (71%)
Arachnodactyly 41 (40%) 30 (43%) 5 (71%)
Facial appearance and craniosynostosis 8 (8%) 6 (9%) 2 (29%)
CTD = connective tissue disorder; FBN1 = fibrillin 1




















Aortic root (cm), mean ± SD 3.4 ± 0.8 3.2 ± 0.7 3.4 ± 0.8 0.4781 2.9 ± 0.7 3.7 ± 0.7 0.0001
‒ Z-score (average absolute devi-
ation)
1.77 1.72 1.37 0.0711 1.55 1.95 0.5925
Ascending aorta (cm), mean ± SD 2.7 ± 0.8 2.6 ± 0.7 2.2 ± 0.4 0.2789 2.1 ± 0.4 3.3 ± 0.6 0.0001
Aortic annulus (cm), mean ± SD 2.3 ± 0.5 2.2 ± 0.4 2.4 ± 0.3 0.3252 2.1 ± 0.5 2.5 ± 0.3 0.0001
Mitral valve prolapse, n (%) 64 (62%) 39 (57%) 4 (57%) 0.9752 29 (63%) 35 (61%) 0.8662
Degree mitral regurgitation, n (%)
‒ none/trivial 74 (72%) 50 (72%) 5 (71%) 0.9542 31 (67%) 43 (75%) 0.3716
‒ mild 22 (21%) 14 (20%) 2 (29%) 0.6142 12 (26%) 10 (18%) 0.2976
‒ moderate 6 (6%) 4 (6%) 0 0.5192 3 (7%) 3 (5%) 0.7888
‒ severe 1 (1%) 1 (1%) 0 0.7524 0 1 (2%) 0.3716
Tricuspid valve prolapse, n (%) 16 (16%) 9 (13%) 2 (29%) 0.2719 6 (13%) 10 (18%) 0.5354
LVEDD (cm), mean ± SD 4.8 ± 0.8 4.7 ± 0.8 4.5 ± 0.8 0.6645 4.3 ± 0.8 5.2 ± 0.7 0.0001
Shortening fraction (%), mean ±
SD
36.1 ± 7.6 36.6 ± 7.6 35 ± 5.9 0.6295 35.2 ± 6.5 36.9 ± 8.3 0.2924
LVEF (%), mean ± SD 57.6 ± 7.8 59.4 ± 6.7 55.7 ± 5.8 0.1944 57.9 ± 6.7 57.5 ± 8.4 0.8414
LVEF <50%, n (%) 9 (9%) 2 (3%) 1 (14%) 0.2616 1 (2%) 8 (14%) 0.0343
CTD = connective tissue disorder; FBN1 = fibrillin 1; LVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; SD = standard deviation
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Medication
A total of 64% (66/103) of patients were under therapy
with a beta-blocker, an angiotensin II receptor blocker
(ARB) and/or an angiotensin converting-enzyme (ACE)
inhibitor (more than one medication possible). Forty pa-
tients (39%) were on beta-blockers, 44 (43%) were on an
ARB and 21 (20%) were on a combination of beta-block-
er and ARB. Other medication included ACE inhibitors in
13 (13%) of patients. Nine percent of patients (9/103) were
under treatment with a statin. Among the 37 patients not on
any medication, we identified 5 adults with a Z-score >3.0.
Family history
Eleven patients (11%) had a family member who suffered
or even died from aortic dissection, 26 (25%) patients had
a relative with an aortic aneurysm, and 14 (14%) had a pos-
itive family history for sudden cardiac death.
Role of genetic testing for confirmation of diagnosis
A systemic score ≥7 (required to document systemic in-
volvement according to the Ghent criteria) was found in
only 40 patients (39%). Thus in 41 patients (41/103, 40%)
a definitive diagnosis was achieved only with additional
information from genetic testing.
Discussion
In our group of 103 patients with clinical suspicion of
MFS, 69 were confirmed as having MFS by genetic testing
and the 2010 Ghent criteria. In seven patients MFS-related
LDS due to mutation in the genes TGFBR1 (LDS1), TGF-
BR2 (LDS2), SMAD3 (LDS3) or TGFB2 (LDS4) was iden-
tified by genetic testing. In 27 patients (26%), MFS was di-
agnosed on the basis of the Ghent criteria without genetic
testing. In our cohort, genetic testing was quite frequent. In
three patients fulfilling the revised Ghent criteria no muta-
tion in any of the tested genes has yet been found. In a large
number of affected patients, the diagnosis of MFS or a re-
lated disorder could be confirmed only by genetic testing
in addition to clinical and echocardiographic examination.
These results demonstrate the steadily growing impact of
genetic testing in patients with suspected CTDs. Genetic
testing often not only confirms the specific diagnosis, but
may in many cases also has an impact on medical treatment
and timing of life-saving aortic surgery.
The frequency and type of cardiovascular surgery in our
cohort was comparable to other centres, with valve-sparing
surgery used as often as possible [13, 14].
Medical therapy was used according to guidelines in 63%
of patients [15, 16].
To date, over 200 heritable CTDs have been described, af-
fecting various organ systems, including heart, blood ves-
sels, bone, eyes, skin, joints and lungs [17]. Over the past
few decades, many of the underlying molecular defects
have been identified, including genes encoding for struc-
tural proteins (e.g., FBN1, COL1A1, COL3A1, COL5A1,
BGN), modifying enzymes (e.g., ADAMTS2, PLOD1), or
components of the transforming growth factor-beta
(TGFβ)-signalling pathways (e.g., SKI, SMAD2/3, TGF-
BR1/2 and TGFB2/3). However, as of now these genes do
not exclusively explain all causes of CTDs and thus many
genes still await discovery [17]. In the majority of pa-
tients with clinical suspicion of MFS, mutations (disease-
causing sequence variants) in FBN1 have been identified;
however, mutations in the genes causing LDS (TGFBR1,
TGFBR2, SMAD3, TGFB2, TGFB3), one of the most im-
portant differential diagnosis of MFS, or in other aortopa-
thy-related genes such as ACTA2, MYH11, MYLK, MAT2A,
MFAP5 and PRKG1 have also been detected. In particular,
patients with mutations in genes causing LDS can present
with distinct and characteristic clinical phenotypes includ-
ing hypertelorism and bifid uvula, both features not found
in MFS. Patients with ACTA2 mutations often have livedo
reticularis and iris flocculi. Such signs can help in the clin-
ical differentiation. However, bifid uvula is not specific for
LDS and has been found in other diseases such as cleft
palate (e.g., SKI-related Shprintzen-Goldberg Syndrome)
or phosphoglucomutase 1 (PGM1) deficiency, a disease
not related to a CTD.
Some CTDs present with distinct clinical phenotypes, but
many of them lead to overlapping clinical features despite
the fact that they are have different genetic aetiologies.
This is one explanation of why the clinical Ghent score
is insufficient for a final diagnosis and illustrates the im-
portance of molecular testing in the diagnosis of MFS and
other CTDs. The frequency of genetic testing in this study
was relatively high and comparable to the data published
by Schoenhoff et al. from Berne [18], the largest MFS cen-
tre in Switzerland (76% in 2014), but considerably high-
er than those from the Mayo Clinic involving 59 patients







Cardiac surgery 34 (33%) 18 (26%) 1 (14%)
Aortic root surgery 31 (30%) 15 (22%) 1 (14%)
‒ Tirone David 18 (17%) 11 (16%) 1 (14%)
‒ composite graft 11 (11%) 4 (6%) 0
‒ exact surgical technique unknown 2 (2%) 0 0
Isolated replacement of aorta ascen-
dens
1 (1%) 1 (1%) 0
Mitral valve surgery 5 (5%) 4 (6%) 0
‒ repair 2 (2%) 2 (3%) 0
‒ replacement 3 (3%) 2 (3%) 0
Tricuspid valve repair 1 (1%) 1 (1%) 0
ICD implantation 1 (1%) 1 (1%) 0
PM implantation 2 (2%) 0 0
CTD = connective tissue disorder; FBN1 = fibrillin 1; ICD = implantable cardioverter defibrillator; PM = pacemaker
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with suspected MFS undergoing aortic root surgery from a
similar time period, where genetic testing was performed
in only 25% [13].
The criteria of the revised Ghent Marfan systemic score
were published in 2010 [6]. A total score of at least 7 is
considered essential in the diagnosis of MFS. However, as
shown in our cohort, the majority of patients (61%) did not
score 7 points. This might be because two of the clinical
features, protrusio acetabuli and dural ectasia, can be found
only radiologically and are thus not routinely assessed, al-
though it is known that dural ectasia, for example, is pre-
sent in 95% of children with MFS [19]. In addition, the
specificity of dural ectasia has never been examined to the
best of our knowledge. Therefore, in current practice the
use of the 2010 Ghent criteria is only somewhat helpful
as they include two criteria that cannot be commonly as-
sessed.
Ectopia lentis, which is not present in LDS, is found in
62% of cases of MFS [20], but can also be an isolated find-
ing not associated with MFS. In our cohort, ectopia lentis
was present in only 28%, which is considerably less than
reports in the current literature. To exclude glaucoma and
cataracts in the MFS eye, patients should have an annu-
al ophthalmological examination. In order to offer tailored
treatment and clinical follow up, molecular genetic testing
should be performed in all patients with suspected MFS or
CTD.
Cardiac interventions
Cardiac surgery was needed in 33%, including aortic root
surgery (30%) and mitral valve surgery (5%). Additionally,
one patient needed an ICD. As expected, most of the car-
diac procedures were on the aortic root. The most frequent
surgical technique was the valve-sparing Tirone David pro-
cedure, which was comparable to other centres [13, 21,
22]. The thresholds used for intervention in the aortic root
were 4.5–5.0 cm in adults with MFS (depending on family
history); the thresholds may be lower if fast growth of the
aortic root is observed or before planned pregnancy. In
LDS, the threshold is 4.2 cm in adults and in children if the
99th percentile of the aortic root is exceeded and the aor-
tic annulus surpasses 1.8–2.0cm [15, 16]. Lower thresholds
are used depending on growth of the aorta, planned preg-
nancy or small size of the patient.
Benefits of the valve-sparing operation are that the patients
keep their own aortic valve and that there is no need of
lifelong anticoagulation, which is desirable especially in
young women who wish to have a child. For 1-year sur-
vival there is no difference between the two techniques,
but severe mitral regurgitation was observed more often af-
ter the valve-sparing surgery [21]. Currently, other surgical
techniques such as PEARS (personalised external aortic
root support) and the Florida sleeve operation play a negli-
gible role in MFS patients [23, 24]. Another option would
be to use an aortic bioprothesis with subsequent percuta-
neous aortic valve replacement if needed. There are limited
data on percutaneous mitral valve reconstruction with Mi-
traClip in MFS [25]. However, there are no data on the per-
formance of percutaneous cardiac interventions on subse-
quent risk of aortic dissection in MFS. Long-term outcome
data in MFS show that aortic surgery in other segments is
quite frequent; even after elective aortic root replacement
the risk of reintervention is more than 10% with about 15%
of patients suffering from type B dissection over time. Af-
ter type A dissection the risk of reintervention is 50% or
higher [26–28].
Medical treatment
Overall, 64% of the patients in our cohort were on some
form of cardiac medical treatment: 39% were treated with
a beta-blocker, 43% with an ARB and 13% with an ACE
inhibitor. These results are similar to recently published
studies [13]. Of the 37 patients not on medication, 23
(62%) were <17 years old and the mean diameters were 3.1
± 0.9 cm for the aortic root and 2.4 ± 0.7 cm for the ascend-
ing aorta. Of those >17 years of age, after excluding the
patients who undergone Tirone David or composite graft
procedures or having Z-score <2.0, we identified 5 patients
with Z-score >3.0 not on medication,
Since 1994, when Shores and colleagues showed that treat-
ment with beta-blockers in MFS patients slows aortic
growth rate, beta-blockers belong to the standard of care
in MFS patients with either aortic root dilatation and/or
positive family history for aortic root dilatation and/or a
mutation know to be associated with an aortic phenotype
[29–32]. Therefore we anticipated a much higher percent-
age of patients under beta-blocker therapy. Our data show
that patient education is important and should be a main fo-
cus in treatment of these patients.
Since ARB therapy has been shown in a MFS mouse mod-
el to have a protective effect on the aorta for aneurysms
and dissection, its use has been widespread [33]. In 2014,
Mueller et al. showed in a cohort of paediatric MFS pa-
tients that ARB and beta-blocker therapy both slow aortic
root dilatation [34]. Losartan and beta-blockers such as
atenolol seem to be equivalent [35]. The Taiwan Marfan
trial and the compare trial both demonstrated that com-
bined therapy with a beta-blocker and ARB was more ef-
fective than beta-blockers alone [36, 37]. Larger trials such
as the Pediatric Heart Network randomised trial of atenolol
versus losartan in children and young adults showed simi-
lar efficacy [38]. Therefore it is up to the treating clinician
to choose a beta-blocker and/or ARB in patients with MFS;
however, at least one of these medications should be used.
There are no data showing that ACE inhibitors are non-in-
ferior to ARB or beta-blocker therapy; some studies have
suggested less efficacy [39]. Calcium channel blockers are
not routinely recommended in the treatment of MFS pa-
tients [40].
Other organ involvement
Regular orthopaedic assessment is strongly recommended
as noncardiovascular procedures are often needed in MFS
patients, including scoliosis surgery, foot surgery, hernioto-
my, lensectomy and pleurodesis after spontaneous pneu-
mothorax. In our cohort, 12% of patients had back surgery
with an incidence of scoliosis of 51%.
Study limitations
Assessment of dural ectasia with magnetic resonance
imaging and hip radiography to assess protrusio acetabuli
were not routinely performed without clinical indication.
Therefore, the Ghent score was most likely underestimat-
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ed. However, in clinical practice, dural ectasia and hip are
not routinely assessed radiographically in most centres.
Clinical genetic testing has become more important to
make or confirm the diagnosis, allowing the identification
and counselling of at-risk relatives as well. However, the
current ability to sequence is greater than the ability to in-
terpret the detected sequence variants with diagnostic and
lifetime value [41].
We retrospectively analysed a limited group of patients
from cardiovascular centres without taking into account
patients from orthopaedic and ophthalmology clinics. We
do not know the impact of this limitation on our data. Be-
sides, we cannot exclude an ascertainment bias and some
patients supposed to have MFS were retrospectively found
to have LDS. However, genetic testing was offered to all
patients in this study group, so there was no bias in that
regard. The selection criteria were such that we included
only patients from the echocardiography database with an
aortic root aneurysm or type A aortic dissection where
analysis of the clinical reported showed at least one feature
suggestive of a CTD. Therefore, the prevalence is falsely
low.
It is a retrospective study from a relatively small cohort,
thus the results have to be confirmed in larger studies. We
are not aware of any patients in the five centres fulfill-
ing the inclusion criteria who were not included and there-
fore this study fulfils the criteria in the STROBE statement
[42].
Conclusion
This study shows that in our centres in Switzerland a high
percentage of patients fulfilling the revised Ghent criteria
for MFS undergo genetic testing, often leading to or con-
firming the diagnosis of MFS. Clinical evaluation in com-
bination with genetic testing is by far superior to clinical
evaluation alone.
Cardiac surgery was performed according to guidelines
and most often for the dilated aortic root [15, 16]. This
study did not analyse long-term outcome and cannot report
the frequency of reintervention, which is considerable in
this cohort.
Only 63% of the patients were under therapy with beta-
blockers, ARBs and/or ACE inhibitors. Thus conservative
management in MFS has to be improved, necessitating
more time for physician/patient interaction.
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